Heartbeam Stock Earnings Reports

HeartBeam reported progress across commercialization, clinical validation, product development and financing in Q1 2026. Commercially, the company signed its first partnership with ClearCardio and added Atelier Health, giving flagship presence in its four target geographies (New York City, Dallas, South Florida, Southern California) and establishing initial foothold in the Direct Pay / concierge market. The core product is a portable, cable‑free device that synthesizes a 12‑lead ECG (the “card”); a working prototype of an on‑demand 12‑lead extended‑wear patch has also been completed and a European pilot for ischemia detection (≈50 patients) has been initiated. Clinical work on heart attack detection is advancing: the ALIGN‑ACS pilot (≈100–120 ER chest pain patients) is enrolling ahead of schedule and expected to complete enrollment by end of Q3 2026; the larger HEADSTART‑ACS study in Indonesia (~500 patients) is government sponsored. HeartBeam announced an AI collaboration with Mount Sinai to develop MI detection and wellness/predictive algorithms and expects clinical data (≈1,000 patients across studies) to support algorithm training and regulatory strategy. Financially, the company completed an $11.5M gross financing in April 2026 (including over‑allotment) and reported a pro forma cash balance of approximately $12.4M. Q1 net loss was $4.7M with $3.6M net cash used in operations (a 19% reduction year‑over‑year). Management expects 2026 cash outflow to be below $16M (down from prior $17–$19M guidance), providing runway into 2027. Near term revenue is expected but modest (H1 is focused on onboarding/validation; H2 2026 should show increased adoption ahead of scaling in 2027). Pricing discussed for subscription is roughly $750–$1,000 annually and management reiterated a breakeven target roughly at ~30,000 patients with a phased go‑to‑market focused on high‑value concierge and preventive cardiology practices.